Share Issue/Capital Change • Sep 30, 2023
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
The number of shares and votes in Xbrane has changed following the issue of 515,108 shares on September 27, 2023 through a directed Set-Off Issue to the Companys lender CVI Investments, Inc. The Company chose to settle the installment of SEK 12,812,487 for the Convertible Bonds with shares. The subscription price in the Set-Off Issue amounts to SEK 24.8734 per share, which equals 90% of the market price (lowest VWAP during the six tradingday period immediately preceding the applicable date).
As of 30 September 2023, the total number of shares and votes in the Company amounts to 29,731,112. The Company's registered share capital amounts to approximately SEK 6,665,301.
Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]
Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-30 14:43 CEST.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.